查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447173

药物混悬剂市场：按类型、按适应症、按最终用户、按分销管道：2023-2032 年全球机会分析和行业预测

Pharmaceutical Suspension Market By Type, By Indication, By End User, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 315 Pages | 商品交期: 2-3个工作天内

价格

2022年药物混悬剂市值为555亿美元，预计2023年至2032年复合年增长率为4.2%，到2032年达到838亿美元。

药物混悬剂市场-IMG1

药物混悬剂是一种在液体介质中具有精细分散的固体颗粒的液体製剂，通常用于口服或肠胃外给药。这些悬浮液提供了多功能的药物传输系统，可提高难溶性药物的稳定性和生物有效性。固体颗粒通常是难溶性药物，均匀分散在液相中以防止沉淀。药物混悬剂具有诸如易于给药、提高患者依从性以及剂量调整灵活性等优点。它在输送具有不同溶解度的药物并确保治疗效果方面发挥着重要作用。该配方的适应性使其成为各种医疗条件的合适选择，有助于其在製药行业的广泛应用。

由于感染疾病、癌症和神经系统疾病等慢性病盛行率的上升，药物混悬剂市场呈现显着成长。根据美国癌症协会的数据，2023 年光是美国就有 1,958,310 例新癌症病例。同样，根据美国国立卫生研究院的数据，全球整体超过 40% 的人患有胃肠道併发症。疾病的迅速增加凸显了对有效药物输送系统的需求。药物混悬剂为药物给药提供了一个多功能平台，并在市场中发挥关键作用。

随着此类慢性疾病变得更加普遍，由于需要满足与此类健康挑战相关的复杂治疗要求，药物混悬液市场有望扩大。然而，由于稳定性和溶解度问题，并非所有药物都可以透过悬浮液有效递送，这限制了药物相容性并阻碍了市场成长。此外，製造复杂性，包括需要专门的设备和工艺，增加了生产成本并限制了製造商的数量，从而限制了市场准入和承受能力。

药物混悬剂市场分为类型、适应症、最终用户、分销管道和地区。依类型划分，市场分为口服製剂、肠胃外製剂等。依适应症分为感染疾病、癌症、肠胃疾病、神经系统疾病等。依最终用户划分，市场分为医院/诊所、居家医疗机构等。按分销管道划分，市场分为医院药房、药局/零售药房和线上提供者。按地区划分，对北美、欧洲、亚太地区和拉丁美洲地区市场进行了分析。

相关人员的主要利益

  • 该报告提供了 2022 年至 2032 年药物混悬剂市场分析的细分市场、当前趋势、估计/趋势分析和动态的定量分析，并确定了一般药物混悬液市场机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商和买家网路的潜力。
  • 对药物混悬液市场细分的详细分析有助于识别市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于对标，并可以清楚了解市场参与者的当前地位。
  • 它还包括对区域和全球药物混悬剂市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

可使用此报告进行客製化（需要额外费用和时间表）

  • 科技趋势分析
  • 国家、区域和全球各级的患者/流行病学资料
  • 监管指引
  • 针对客户兴趣的其他公司简介
  • 公司简介的扩充列表
  • 历史市场资料
  • SWOT分析

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 药物开发活动增加
      • 患者对混悬液配方的依从性
      • 学名药的可用性
    • 抑制因素
      • 药物相容性限制
    • 机会
      • 加大倡议拓展市场

第四章 药物混悬液市场：依类型

  • 概述
  • 口服剂
  • 注射剂
  • 其他的

第五章 药物混悬液市场：依适应症分类

  • 概述
  • 感染疾病
  • 癌症
  • 消化器官
  • 神经
  • 其他的

第六章 药物混悬液市场：依最终使用者分类

  • 概述
  • 医院和诊所
  • 居家医疗
  • 其他的

第七章 药物混悬液市场：依分销管道

  • 概述
  • 医院药房
  • 药局和零售药局
  • 线上提供者

第八章 药物混悬液市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第9章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第十章 公司简介

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Eli Lilly and Company.
  • Bayer AG
  • Sanofi
  • Lupin
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
Product Code: A12351

The The pharmaceutical suspension market was valued at $55.5 billion in 2022, and is estimated to reach $83.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

Pharmaceutical Suspension Market - IMG1

Pharmaceutical suspensions are liquid formulations comprising finely dispersed solid particles in a liquid medium, often for oral or parenteral administration. These suspensions provide a versatile drug delivery system allowing for enhanced stability and bioavailability of poorly soluble drugs. The solid particles, typically insoluble drugs, are uniformly dispersed in the liquid phase, preventing settling. Pharmaceutical suspensions offer advantages such as ease of administration, improved patient compliance, and flexibility in dosage adjustments. They play a crucial role in delivering drugs with variable solubility profiles, ensuring therapeutic efficacy. The formulation's adaptability makes it a preferred choice for diverse medical conditions, contributing to its widespread use in the pharmaceutical industry.

The pharmaceutical suspensions market is witnessing significant growth, attributed to rise in prevalence of chronic conditions such as infectious diseases, cancer, and neurological disorders. According to the American Cancer Society, in 2023, the U.S. alone accounted for 1,958,310 new cancer cases. Similarly, according to the National Institutes of Health, more than 40% of people globally suffer from gastrointestinal complications. This surge in disease incidence emphasizes the critical need for effective drug delivery systems. Pharmaceutical suspensions play a pivotal role in the market, offering a versatile platform for administering medications.

As these chronic conditions become more pervasive, the pharmaceutical suspensions market is poised for expansion, driven by the imperative to address the complex treatment requirements associated with such health challenges. However, limited drug compatibility hinders the market growth as not all medications are effectively delivered through suspensions due to stability and solubility issues. In addition, manufacturing complexities such as requiring specialized equipment and processes, increase production costs and restrict the number of manufacturers, limiting market accessibility and affordability.

The pharmaceutical suspension market is segmented into type, indication, end user, distribution channel, and region. On the basis of type, the market is segmented into oral, parenteral, and others. On the basis of indication, it is segmented into infectious diseases, cancer, gastrointestinal, neurological, and others. On the basis of end user, the market is segmented into hospitals and clinics, home care settings, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug store and retail pharmacies, and online providers. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players that operate in the pharmaceutical suspension market include Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Eli Lilly and Company, Bayer AG, Sanofi, Lupin, Glenmark Pharmaceuticals Limited, Novartis AG, and Teva Pharmaceutical Industries Limited. The key players have adopted key strategies such as product approval and collaboration to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical suspension market analysis from 2022 to 2032 to identify the prevailing pharmaceutical suspension market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pharmaceutical suspension market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pharmaceutical suspension market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Technology Trend Analysis
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Oral
  • Parenteral
  • Others

By Indication

  • Infectious Diseases
  • Cancer
  • Gastrointestinal
  • Neurological
  • Others

By End User

  • Hospitals and Clinics
  • Home Care Settings
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • AstraZeneca plc
    • Eli Lilly and Company.
    • Sanofi
    • Lupin
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc.
    • Bayer AG
    • Glenmark Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. High threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increased Drug Development Activities
      • 3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
      • 3.4.1.3. Availability of generic pharmaceutical suspensions
    • 3.4.2. Restraints
      • 3.4.2.1. Limited drug compatibility
    • 3.4.3. Opportunities
      • 3.4.3.1. Growing initiatives for market expansion

CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Oral
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Parenteral
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Gastrointestinal
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Neurological
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Others
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals and Clinics
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Home Care Settings
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Drug Store and Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Providers
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Type
    • 8.2.3. Market size and forecast, by Indication
    • 8.2.4. Market size and forecast, by End User
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Type
      • 8.2.6.1.2. Market size and forecast, by Indication
      • 8.2.6.1.3. Market size and forecast, by End User
      • 8.2.6.1.4. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Type
      • 8.2.6.2.2. Market size and forecast, by Indication
      • 8.2.6.2.3. Market size and forecast, by End User
      • 8.2.6.2.4. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Type
      • 8.2.6.3.2. Market size and forecast, by Indication
      • 8.2.6.3.3. Market size and forecast, by End User
      • 8.2.6.3.4. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Type
    • 8.3.3. Market size and forecast, by Indication
    • 8.3.4. Market size and forecast, by End User
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Type
      • 8.3.6.1.2. Market size and forecast, by Indication
      • 8.3.6.1.3. Market size and forecast, by End User
      • 8.3.6.1.4. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Type
      • 8.3.6.2.2. Market size and forecast, by Indication
      • 8.3.6.2.3. Market size and forecast, by End User
      • 8.3.6.2.4. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Type
      • 8.3.6.3.2. Market size and forecast, by Indication
      • 8.3.6.3.3. Market size and forecast, by End User
      • 8.3.6.3.4. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Type
      • 8.3.6.4.2. Market size and forecast, by Indication
      • 8.3.6.4.3. Market size and forecast, by End User
      • 8.3.6.4.4. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Type
      • 8.3.6.5.2. Market size and forecast, by Indication
      • 8.3.6.5.3. Market size and forecast, by End User
      • 8.3.6.5.4. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Type
      • 8.3.6.6.2. Market size and forecast, by Indication
      • 8.3.6.6.3. Market size and forecast, by End User
      • 8.3.6.6.4. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Type
    • 8.4.3. Market size and forecast, by Indication
    • 8.4.4. Market size and forecast, by End User
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Type
      • 8.4.6.1.2. Market size and forecast, by Indication
      • 8.4.6.1.3. Market size and forecast, by End User
      • 8.4.6.1.4. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Type
      • 8.4.6.2.2. Market size and forecast, by Indication
      • 8.4.6.2.3. Market size and forecast, by End User
      • 8.4.6.2.4. Market size and forecast, by Distribution Channel
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Type
      • 8.4.6.3.2. Market size and forecast, by Indication
      • 8.4.6.3.3. Market size and forecast, by End User
      • 8.4.6.3.4. Market size and forecast, by Distribution Channel
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Type
      • 8.4.6.4.2. Market size and forecast, by Indication
      • 8.4.6.4.3. Market size and forecast, by End User
      • 8.4.6.4.4. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Type
      • 8.4.6.5.2. Market size and forecast, by Indication
      • 8.4.6.5.3. Market size and forecast, by End User
      • 8.4.6.5.4. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Type
      • 8.4.6.6.2. Market size and forecast, by Indication
      • 8.4.6.6.3. Market size and forecast, by End User
      • 8.4.6.6.4. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Type
    • 8.5.3. Market size and forecast, by Indication
    • 8.5.4. Market size and forecast, by End User
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Type
      • 8.5.6.1.2. Market size and forecast, by Indication
      • 8.5.6.1.3. Market size and forecast, by End User
      • 8.5.6.1.4. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Type
      • 8.5.6.2.2. Market size and forecast, by Indication
      • 8.5.6.2.3. Market size and forecast, by End User
      • 8.5.6.2.4. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Type
      • 8.5.6.3.2. Market size and forecast, by Indication
      • 8.5.6.3.3. Market size and forecast, by End User
      • 8.5.6.3.4. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Type
      • 8.5.6.4.2. Market size and forecast, by Indication
      • 8.5.6.4.3. Market size and forecast, by End User
      • 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Pfizer Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Merck & Co., Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. AstraZeneca plc
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Eli Lilly and Company.
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Bayer AG
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. Sanofi
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Lupin
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
    • 10.7.7. Key strategic moves and developments
  • 10.8. Glenmark Pharmaceuticals Limited
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. Novartis AG
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Teva Pharmaceutical Industries Limited
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PHARMACEUTICAL SUSPENSION MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 06. PHARMACEUTICAL SUSPENSION MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PHARMACEUTICAL SUSPENSION MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. PHARMACEUTICAL SUSPENSION MARKET FOR GASTROINTESTINAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. PHARMACEUTICAL SUSPENSION MARKET FOR NEUROLOGICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. PHARMACEUTICAL SUSPENSION MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. PHARMACEUTICAL SUSPENSION MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. PHARMACEUTICAL SUSPENSION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 25. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. UK PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 52. UK PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. UK PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 56. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 85. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. PFIZER INC.: KEY EXECUTIVES
  • TABLE 117. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 118. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 119. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 120. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 121. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 122. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 123. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 124. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 125. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 126. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 127. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 128. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 129. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 130. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 131. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
  • TABLE 132. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 133. BAYER AG: KEY EXECUTIVES
  • TABLE 134. BAYER AG: COMPANY SNAPSHOT
  • TABLE 135. BAYER AG: PRODUCT SEGMENTS
  • TABLE 136. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 137. SANOFI: KEY EXECUTIVES
  • TABLE 138. SANOFI: COMPANY SNAPSHOT
  • TABLE 139. SANOFI: PRODUCT SEGMENTS
  • TABLE 140. SANOFI: PRODUCT PORTFOLIO
  • TABLE 141. LUPIN: KEY EXECUTIVES
  • TABLE 142. LUPIN: COMPANY SNAPSHOT
  • TABLE 143. LUPIN: PRODUCT SEGMENTS
  • TABLE 144. LUPIN: PRODUCT PORTFOLIO
  • TABLE 145. LUPIN: KEY STRATERGIES
  • TABLE 146. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 147. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 148. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 149. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 150. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 151. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 152. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 153. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 154. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 155. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 156. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 157. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 158. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 159. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. PHARMACEUTICAL SUSPENSION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PHARMACEUTICAL SUSPENSION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN PHARMACEUTICAL SUSPENSION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACEUTICAL SUSPENSION MARKET (2023-2032)
  • FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. HIGH THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL PHARMACEUTICAL SUSPENSION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR GASTROINTESTINAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR NEUROLOGICAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. PHARMACEUTICAL SUSPENSION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 30. U.S. PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CANADA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. MEXICO PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. GERMANY PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. FRANCE PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. UK PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. ITALY PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SPAIN PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. JAPAN PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. CHINA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. INDIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: PHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2022
  • FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. SANOFI: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 75. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 76. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 77. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 78. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 79. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 80. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)